- Important Safety Information
- Prescribing Information
- Request Samples
- Patient Co-Pay Offer
- ALREXPro.com
- Legal Notice
- Privacy Policy
BEPREVE RELIEVES THE ITCH ASSOCIATED WITH OCULAR ALLERGIES1,2
GET PROVEN RELIEF FOR ITCH
Learn how BEPREVE relieves the itch associated with ocular allergies
Indications and Usage
BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.
Important Safety Information
- BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients.
- To minimize contaminating the dropper tip and solution, advise the patient not to touch the eyelids or surrounding areas with the dropper tip of the bottle and to keep the bottle tightly closed when not in use.
- BEPREVE should not be used to treat contact lens-related irritation.
- Patient should remove contact lenses prior to instillation of BEPREVE, because benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes after BEPREVE administration.
- The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for Prescribing Information for BEPREVE.
References: 1. BEPREVE [package insert]. Tampa, FL: Bausch & Lomb Incorporated. 2019. 2. Muñoz M, Williams JI, Gow JA, Schooley GL, McNamara TR; for the Bepotastine Ophthalmic Solutions Clinical Study Group. Bepotastine besilate ophthalmic solution 1.5% provides a rapid and sustained reduction in ocular itch for severely allergic subjects following exposure to ragweed or grass pollens using the conjunctival allergen challenge (CAC) model of allergic conjunctivitis. Poster presented at: 2011 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology; November 3-8, 2011; Boston, MA. Poster P341.
Indications and Usage
BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.
Important Safety Information
- BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients.
- To minimize contaminating the dropper tip and solution, advise the patient not to touch the eyelids or surrounding areas with the dropper tip of the bottle and to keep the bottle tightly closed when not in use.
- BEPREVE should not be used to treat contact lens-related irritation.
- Patient should remove contact lenses prior to instillation of BEPREVE, because benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes after BEPREVE administration.
- The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for Prescribing Information for BEPREVE.
THIS WEBSITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.
Please choose an option below: